TRIAL DETAIL
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
2 |
Start Date 11/01/2009 |
Age of Trial (yrs) 15.5 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
IGF1R inhibitor + mTOR Inhibitor |
|||
Strategy: |
Block related tumor signal paths |
|||
Trial Type: |
GIST not specified. GIST patients known to be enrolled. |
|||
Other Protocol IDs: |
CDR0000659358, MSKCC-09097 |
|||
Sponsor: |
Memorial Sloan-Kettering Cancer Center |
|||
Patient Contact: |
||||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Intravenous |
|||
Trial Notes: |
From Clinical Trials.gov Disease Characteristics: Confirmation of IGF1R status in pre-existing tumor specimens by IHC. From MSKCC website: Patients must have a confirmed diagnosis of locally advanced, recurrent, and/or metastatic sarcoma (soft tissue or bone) that contains the insulin-like growth factor 1 receptor. For an early part of the study, patients will be allowed to receive treatment regardless of whether their tumor tests positive or negative. |
|||
Trial Links |
Trial Results |
Drug Information |
| CCI-779 (temsirolimus) in Wikipedia |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
1275 York Ave |
New York |
NY |
10065 |
USA |
|
5841 S. Maryland Ave |
Chicago |
IL |
60637 |
USA |